Vishal Bhatnagar, MD
@vishalbmd
Followers
261
Following
457
Media
5
Statuses
40
Associate Director for Patient Outcomes, Oncology Center of Excellence. FDA. Interested in MM and patient focused drug development. Opinions/tweets are my own
Washington, DC
Joined November 2017
RT @FDAOncology: Today's the day for FDA's 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop on patient-reported ou….
0
5
0
RT @FDAOncology: FDA Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop. June 29, 2022. Agenda and session panelist biog….
0
5
0
RT @FDAOncology: Mark your calendar and register for the FDA 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop focu….
0
5
0
Listen in to two fantastic sessions moderated by @FDAOncology deputy director @pkluetz!.
Happening now: Day 2 of the COA-CCT workshop. Sessions 3 & 4 moderated by OCE Deputy Director @pkluetz – important panel discussions about patient-reported physical function. #OCEOutcomes21.
2
1
6
An important draft guidance for those interested in rigorous measurement of PRO in oncology trials!.
Check out a new FDA draft guidance with recommendations to sponsors for collection of a core set of patient-reported clinical outcomes in cancer clinical trials and related considerations for instrument selection and trial design. We welcome comments!.
0
2
12
RT @FDAMedia: Today, the FDA issued draft guidance to address which patient-reported outcomes to measure in cancer clinical trials. https:/….
0
5
0
Excited for this workshop, focused on better characterizing patient-reported physical function! @FDAOncology.
Registration is now open and free! FDA 6th Annual Clinical Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop-July 21 & 3,2021 (virtual) #OCEOutcomes21.@pkluetz @vishalbmd @EGHorod.
0
0
7
Did you know that #FDAOncology supports applied regulatory science research to address practical problems in oncology therapy development? Check out FDA’s Broad Agency Announcement. More info at the #OCEScientificCollaborative:
0
0
2
RT @FDAOncology: Did you know that #FDAOncology supports applied regulatory science research to address practical problems in oncology ther….
0
3
0
RT @ESPNNFL: Mo Gaba, who battled cancer and was blind, became part of the fabric in the Baltimore sports community and made a lasting impa….
0
646
0
RT @NEJM: Why has the United States handled this pandemic so badly? The Editors note that although we came into this crisis with enormous a….
0
15K
0
RT @ScottGottliebMD: FDA’s professional staff have acted with a sense of high urgency during Covid, driven by a shared sense of public heal….
0
87
0
RT @pkluetz: Informative visualization of the timing of FDA review when multiple expedited programs are put in place. A lot goes into haste….
0
6
0
Patient-reported overall side effect bother is key to assessing tolerability. Listen to @pkluetz moderate a discussion w/ @unbiasedlaura @GitaThanaMD @JFreemanDaily @SpiveySandra @pre_ryan, Dr Sandra Mitchell and Dr David Cella. Tune in now! #OCEOutcomes20.
0
4
18
RT @drmelcalvert: Why timing really matters in #pro assessment. @BellKingKal describes how we may miss important side effects if we assess….
0
7
0
RT @RKouzyMD: Really excited to hear about project patient voice which will allow healthcare providers to access PRO data collected from ca….
0
1
0
RT @IshwariaMD: Folks you can't ask the right question at the wrong time! Timing of #PRO measurements must adapt as #cancer treatments (esp….
0
11
0
Happening now: @FDAOncology @ASCO COA-CCT workshop Session 2, moderated by @BellKingKal - and important discussion about PRO assessment frequency #OCEOutcomes20.
0
2
8
RT @FDAOncology: We're getting ready to welcome you online tomorrow, July 17, for the FDA-@ASCO Clinical Outcome Assessments in Cancer Clin….
0
14
0